{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:52:12Z","timestamp":1782301932039,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"DOI":"10.7759\/cureus.111414","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:45:47Z","timestamp":1782301547000},"source":"Crossref","is-referenced-by-count":0,"title":["The Botox Paradox: How Rising Drug Costs and Reimbursement Failures Threaten Access to Botulinum Toxin Therapy in Neurology"],"prefix":"10.7759","author":[{"given":"Patricio S","family":"Espinosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick DW","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, et al.. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010, 50:921-36. 10.1111\/j.1526-4610.2010.01678.x","journal-title":"Headache"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616677005","article-title":"Botulinum toxin in the management of chronic migraine: clinical evidence and experience","volume":"10","author":"Escher CM","year":"2017","unstructured":"Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017, 10:127-35. 10.1177\/1756285616677005","journal-title":"Ther Adv Neurol Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson DM","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ, et al.. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016, 86:1818-26. 10.1212\/WNL.0000000000002560","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.1.99","article-title":"A primer on brand-name prescription drug reimbursement in the United States","volume":"30","author":"Hernandez I","year":"2024","unstructured":"Hernandez I, Hung A. A primer on brand-name prescription drug reimbursement in the United States. J Manag Care Spec Pharm. 2024, 30:99-106. 10.18553\/jmcp.2024.30.1.99","journal-title":"J Manag Care Spec Pharm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004025","article-title":"Racial disparities in neurologic health care access and utilization in the United States","volume":"88","author":"Saadi A","year":"2017","unstructured":"Saadi A, Himmelstein DU, Woolhandler S, Mejia NI. Racial disparities in neurologic health care access and utilization in the United States. Neurology. 2017, 88:2268-75. 10.1212\/WNL.0000000000004025","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-024-11921-0","article-title":"Barriers accessing specialty care in the United States: a patient perspective","volume":"24","author":"Schuldt R","year":"2024","unstructured":"Schuldt R, Jinnett K. Barriers accessing specialty care in the United States: a patient perspective. BMC Health Serv Res. 2024, 24:1549. 10.1186\/s12913-024-11921-0","journal-title":"BMC Health Serv Res"},{"key":"ref7","article-title":"Neurotoxin waste from drawing product through the vial stopper","volume":"7","author":"Niamtu J 3rd","year":"2014","unstructured":"Niamtu J 3rd. Neurotoxin waste from drawing product through the vial stopper. J Clin Aesthet Dermatol. 2014, 7:33-7.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1852","article-title":"Administrative burden and costs of prior authorizations in a dermatology department","volume":"156","author":"Carlisle RP","year":"2020","unstructured":"Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM. Administrative burden and costs of prior authorizations in a dermatology department. JAMA Dermatol. 2020, 156:1074-8. 10.1001\/jamadermatol.2020.1852","journal-title":"JAMA Dermatol"},{"key":"ref9","unstructured":"Prior authorization is a major practice burden. How do you compare? American Medical Association. (2018). Accessed. June 16, 2026: https:\/\/www.ama-assn.org\/practice-management\/sustainability\/prior-authorization-major-practice-burden-how-do-you-compare."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2019.82795","article-title":"The whole truth about botulinum toxin - a review","volume":"37","author":"Witmanowski H","year":"2020","unstructured":"Witmanowski H, B\u0142ochowiak K. The whole truth about botulinum toxin - a review. Postepy Dermatol Alergol. 2020, 37:853-61. 10.5114\/ada.2019.82795","journal-title":"Postepy Dermatol Alergol"},{"key":"ref11","article-title":"A retrospective cost analysis of patients who switched from onabotulinumtoxinA to incobotulinumtoxinA in a private neurology practice","volume":"13","author":"Karschney VK","year":"2020","unstructured":"Karschney VK, Greeley DR. A retrospective cost analysis of patients who switched from onabotulinumtoxinA to incobotulinumtoxinA in a private neurology practice. Am Health Drug Benefits. 2020, 13:205-10.","journal-title":"Am Health Drug Benefits"},{"key":"ref12","unstructured":"Centers for Medicare & Medicaid Services. Qualified Medicare Beneficiary Program. https.\/\/www.cms.gov\/medicare\/medicaid-coordination\/about\/qualified-medicare-beneficiary-program."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong D","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, et al.. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005, 20:783-91. 10.1002\/mds.20403","journal-title":"Mov Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251370769","article-title":"OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial","volume":"45","author":"Pozo-Rosich P","year":"2025","unstructured":"Pozo-Rosich P, Blumenfeld AM, Lipton RB, et al.. OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial. Cephalalgia. 2025, 45:3331024251370769. 10.1177\/03331024251370769","journal-title":"Cephalalgia"},{"key":"ref15","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018, 38:1-211.","journal-title":"Cephalalgia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2025.017","article-title":"American Society of Plastic Surgeons. Botulinum Toxin Cost. [17] Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","year":"2019","unstructured":"American Society of Plastic Surgeons. Botulinum Toxin Cost. [17] Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide. a new era in migraine therapy. Lancet. 2019, 394:1765-1774. 10.18773\/austprescr.2025.017","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine","volume":"16","author":"Katsarava Z","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012, 16:86-92. 10.1007\/s11916-011-0233-z","journal-title":"Curr Pain Headache Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"Charles A","year":"2019","unstructured":"Charles A, Pozo-Rosich P. . Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019, 394:1765-74. 10.1016\/S0140-6736(19)32504-8","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505639-the-botox-paradox-how-rising-drug-costs-and-reimbursement-failures-threaten-access-to-botulinum-toxin-therapy-in-neurology","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:45:54Z","timestamp":1782301554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505639-the-botox-paradox-how-rising-drug-costs-and-reimbursement-failures-threaten-access-to-botulinum-toxin-therapy-in-neurology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.111414","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}